Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SI | P14410 | 2/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.31 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.31 |
| ▸ | WEE1 | P30291 | 1/20 | 0.31 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1149533 | 0.90 | HSP90AA1 (0.37) | MGAMGAASIMGAM2HSP90AA1 | |
| SCHEMBL1148593 | 0.86 | MGAM (0.36) | MGAMGAASIMGAM2HSP90AA1 | |
| SCHEMBL1147862 | 0.86 | HSP90AA1 (0.38) | MGAMGAASIMGAM2HSP90AA1 | |
| SCHEMBL1148550 | 0.84 | HSP90AA1 (0.37) | HSP90AA1KCNMA1ANPEPDPP4 | |
| SCHEMBL1148503 | 0.84 | ANPEP (0.34) | HSP90AA1KCNMA1CYP1A2ANPEPDPP4 | |
| SCHEMBL1148468 | 0.82 | MEN1 (0.39) | GAACYP1A2CYP2C19MAOAMAOB | |
| SCHEMBL5329381 | 0.81 | TRPA1 (0.40) | MGAMGAASIMGAM2KCNMA1 | |
| SCHEMBL2521030 | 0.81 | DHODH (0.32) | MGAMGAASIMGAM2KCNMA1 | |
| SCHEMBL1147781 | 0.80 | ESR1 (0.35) | CYP1A2CYP2C19ESR1ESR2 | |
| SCHEMBL1148350 | 0.80 | ALOX5 (0.41) | GAAHSP90AA1KCNMA1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188075-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-05-29 | — | — | US | claimed |
| EP-2298748-A2 | Triazole compounds that modulate HSP90 activity | Synta Pharmaceuticals Corp. (US) | 2011-03-23 | — | — | EP | claimed |
| US-7825148-B2 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2010-11-02 | — | — | US | claimed |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP | 2010-04-15 | — | — | US | claimed |
| EP-2054059-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2009-05-06 | — | — | EP | claimed |
| WO-2008021364-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2008-02-21 | — | — | WO | claimed |
| EP-1817295-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006055760-A9 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2006-09-21 | — | — | WO | claimed |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-07-27 | — | — | US | claimed |
| WO-2006055760-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-26 | — | — | WO | claimed |
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2019-05-16 | — | — | US | disclosed |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2017-11-09 | — | — | US | disclosed |
| EP-2295416-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP. | 2010-09-30 | — | — | US | disclosed |
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. | 2008-05-29 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| WO-2007139952-A2 | METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS WITH HSP90 MODULATING ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | HSP90AB1, HSP90AA1, HSP90AB2P | MGAM 2866/4885GAA 589/4885SI 1129/4885 |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90AB2P | MGAM 4638/4885GAA 1169/4885SI 3597/4885 |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | MGAM 873/4885GAA 107/4885SI 3180/4885 |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | MGAM 1715/4885GAA 706/4885SI 1456/4885 |
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | MGAM 609/4885GAA 655/4885SI 481/4885 |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | MGAM 609/4885GAA 655/4885SI 481/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | MGAM 985/4885GAA 320/4885SI 3710/4885 |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | HSP90AB1, HSP90AB2P, HSP90AA1 | MGAM 4388/4885GAA 2305/4885SI 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.